Figure 1.

Overview of Cancer Drug Response profile scan (CDRscan). (a) Two main applications of CDRscan and dataset structure. For any given genomic fingerprint (i.e., a list of somatic mutations) of a tumour, CDRscan predicts which of 244 Genomics in Drug Sensitivity in Cancer (GDSC) anticancer drugs would be effective. The input of CDRscan can be molecular information of a particular small molecule for which CDRscan reports the predicted sensitivity of 787 cancer cell lines. The datasets used to train CDRscan were extracted from COSMIC cell line project (CCLP) and GDSC databases which represent 787 cancer cell lines across 25 cancer types defined by TCGA, 28,328 mutation positions in 567 cancer associated genes, and assay results from treatment of 244 anticancer drugs. (b) Data filtering procedure and final datasets. CCLP and GDSC databases contain genomic characterisation of 1,001 cancer cell lines and IC₅₀ values measured from treatment of 1,001 cell lines with 265 anticancer drugs. The datasets were refined to include only the 567 Cosmic Cancer Gene Census genes and the cancer types that have at least 10 cell lines. Drugs without PubChem Compound Identifier or having molecular weight greater than 1000 g/mol were excluded. Totals of 28,328 and 3,072 features were extracted from cell line genomic signatures and drugs, respectively, constituting binary encoding of 31,400 features in total. The graphical image used in Fig. 1a is an original creation by Ye-Bin Jung and is reprinted under a CC BY license with permission from Ye-Bin Jung. All rights reserved.